*Sponsored by Lifewater Media. Please see disclosures below. |
| Get "CTXR" on Your Radar! |
| | | | | Folks, We have an exciting stock idea for you today! Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products. | | | The company has a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy, and unique prescription products. When it comes to the biotech sector, the bigger the pipeline the more opportunities a stock has to shine. Speaking of which... One of Citius's brightest stars is LYMPHIR, a previously FDA-approved cancer immunotherapy for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL). Citius plans to further explore the potential of LYMPHIR to treat larger patient populations with additional indications in peripheral T-cell lymphoma (PTCL) and immuno-oncology. This could mean more market potential and additional catalyst opportunities for the company. Even without it, there may be a sizable opportunity for Citius... | | | The company projects a total addressable market between $300 million and $400+ million! One of the exciting aspects is the relatively limited competition. There are currently only three other CTCL treatment options, and the specific mechanism through which LYMPHIR operates is unique (according to Citius Pharma). | | | Speaking of catalyst opportunities... The company recently received FDA approval for LYMPHIR, marking a significant milestone! This development is likely top of mind for investors and speculators, considering the potential impact of such a breakthrough. Another product in Citius's pipeline is Mino-Lok... This is a novel antibiotic lock solution designed to salvage catheters in patients with catheter-related
bloodstream infections. Why is this a big deal? According to Citius, there are currently no pharmaceuticals approved to deal with this issue for patients with central-line associated bloodstream infections. | | | Keep in mind that there are around 7 million Central Venus Catheters used annually in the United States... The market potential is estimated (according to Citius Pharma) to be over $1 billion in the US alone and over $2 billion globally! While there are no specific catalyst dates looming for this product, you never know when the next big piece of news will drop. We have been discussing the fundamental side of things up until now; however, it is important not to ignore the technicals... CTXR may have found support around the $0.33 price range and is showing some strength over the past couple of days! | | | A push beyond the $0.5 price point would give us a potential indication that the bulls are in control of the party. Anyways...
That's all for now!
Until Next Time, -Damian | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Sponsored by Lifewater Media. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to punjabsvera@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated nineteen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) on November 11, 2024. ZipTrader may receive additional campaigns in the future by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR). ZipTrader has been compensated seventeen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) from August 4, 2024 to August 5, 2024. ZipTrader has been compensated twenty thousand USD by ACH Bank Transfer by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR) on January 25, 2023. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Oncology Inc.* (CTOR) on September 23, 2024. As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Citius Pharmaceuticals Inc. (CTXR). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Citius Pharmaceuticals Inc. (CTXR), increased trading volume, and possibly an increased share price of Citius Pharmaceuticals Inc. (CTXR), which may or may not be temporary and decrease once the marketing arrangement has ended. *Citius Oncology Inc. (CTOR) is a subsidiary of Citius Pharmaceuticals Inc. (CTXR) |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service.See Our Advertisement/Sponsored Stock Disclaimer. |
| | |
|
|
|---|
|
|
|
